News Xintela AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 14:38:51 14/05/2024 BST			5-day change	1st Jan Change
0.249 ^SEK	0.00%		-6.04%	-8.12%

02-28	Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
02-20	Xintela Names New Chief Scientific Officer	MT

Xintela AB publishes Annual Report 2023	04-17	AQ
Xintela: Awaiting results in trials and discussions	02-29	AQ
Xintela AB Year-end Report 2023	02-28	AQ
Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Xintela Names New Chief Scientific Officer	02-20	MT
Xintela appoints Lucienne Vonk as Chief Scientific Officer	02-19	AQ
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	02-19	CI
Targinta's CEO to BioStock: "Strong interest in ADCs in 2023"	01-22	AQ
Xintela newsletter, No. 1 2024	01-19	AQ
First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers	12-21	AQ
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	12-21	CI
Xintela publishes efficacy results with EQSTEM from preclinical equine OA study	12-20	AQ
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	12-20	CI
Västra Hamnen Corporate Finance initiates coverage of Xintela	12-04	AQ
Xintela’s integrin marker carries hidden value	12-01	AQ
Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)	11-30	AQ
Xintela AB Interim Report January - September 2023	11-24	AQ
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-24	CI
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study	13/10/23	AQ
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	13/10/23	CI

No results for this search